Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mallinckrodt Vision For Growth Emphasizes Acthar, Ofirmev

Executive Summary

The specialty pharma laid out plans for driving future growth after completing two acquisitions earlier this year. Two of the key drivers will be drugs acquired in those deals – along with more business development.

You may also be interested in...



Mallinckrodt's FTC Settlement Seems A Blip For Acthar Blockbuster

Company anticipates steady sales of its blockbuster treatment for infantile spasms and other severe conditions for many years, despite agreement to out-license a potential competitor as part of settlement with US trade commission. Settlement resolving investigation into earlier Questcor acquisition also includes $100m fine.

Questcor Expansion Strategy Pays Off For Acthar

Questcor has successfully revived a decades-old product by raising the drug’s price, securing a new approval in a niche orphan indication in infants and making a commercial push in areas like multiple sclerosis and rheumatoid arthritis.

Cadence Builds Case For Branded IV Acetaminophen; Can It Reduce Opioid Use?

After rebounding from regulatory setbacks, Cadence Pharmaceuticals Inc. intravenous acetaminophen Ofirmev has been approved by FDA with a label many analysts praise as broad and positive.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel